Drugs / IFN-β-1a
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00616187 Comparator | Oct 2003 → Jun 2007 | relapsing-remitting multiple sclerosis | Charite University, Berlin, Germany | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IFN-β-1a | “IFN-β-1a 22 µg s.c. 3 times weekly” NCT00616187 ↗ |
| Route | Subcutaneous | “IFN-β-1a 22 µg s.c. 3 times weekly” NCT00616187 ↗ |